The first two pilot studies assessing the effect of SGLT2 inhibitors with CPET in the human population investigated the effect of treatment with empagliflozin for one month in HFrEF patients with T2DM in a non-placebo-controlled study protocol [207,209]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.